Mind Medicine (MindMed) Inc. (MNMD) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Mind Medicine (MindMed) I... (MNMD)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

6.37

-0.13 (-1.92%)

At close: Jan 14, 2025, 3:59 PM

6.47

1.64%

After-hours Jan 14, 2025, 07:54 PM EST

undefined% (undefined)

Bid	6.09
Market Cap	466.76M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.71
PE Ratio (ttm)	-3.72
Forward PE	n/a
Analyst	Buy

Ask	6.89
Volume	754,790
Avg. Volume (20D)	1,371,185
Open	6.65
Previous Close	6.50
Day's Range	6.23 - 6.65
52-Week Range	3.49 - 12.22
Beta	undefined

About MNMD

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has com...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 15, 2016

Employees 57

Stock Exchange NASDAQ

Ticker Symbol MNMD

Website https://www.mindmed.co

Analyst Forecast

According to 9 analyst ratings, the average rating for MNMD stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 214.22% from the latest price.

Buy 88.89%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

+5.65%

Mind Medicine shares are trading higher. HC Wainwr... Unlock content with Pro Subscription

2 months ago · Source

+12.9%

Mind Medicine shares are trading higher after the company reported better-than-expected Q3 EPS results.

News

1 week ago · fool.com

Why Mind Medicine Stock Is Soaring Today

Mind Medicine (MNMD 8.97%) stock is posting big gains in Tuesday's trading. The biotech company's share price was up 8.7% as of 2 p.m.

3 weeks ago · zacks.com

MindMed Stock Skyrockets 94% Year to Date: What's Driving It?

2024 was a transformational year for MNMD as it executed many important milestones.

3 weeks ago · zacks.com

5 Biotech Breakthrough Stocks to Watch in 2025

After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointmen...

3 weeks ago · businesswire.com

MindMed to Be Added to the Nasdaq Biotechnology Index

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain heal...

1 month ago · businesswire.com

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain heal...

1 month ago · businesswire.com

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

1 month ago · businesswire.com

MindMed Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain healt...

2 months ago · seekingalpha.com

Mind Medicine: No News = Good News

Mind Medicine's share price has responded very strongly to a third quarter update that contained very little new information. The market appears to have moved to a bullish stance following confirmatio...

2 months ago · seekingalpha.com

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Stephanie Fagan – Chief Corporate Affairs Officer Rob Barrow – Chief Execu...

2 months ago · seekingalpha.com

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

Mind Medicine (MindMed) Inc. is advancing MM-120 for GAD with two phase 3 trials, VOYAGE and PANORAMA, starting in late 2024 and early 2025. MM-120 is also being tested for MDD in the phase 3 EMERGE s...